Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
Fiche publication
Date publication
octobre 2018
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Dr DALAC Sophie, Dr GRANEL-BROCARD Florence
Tous les auteurs :
Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, Borget I
Lien Pubmed
Résumé
Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which showed significant improvement in survival. In France, in 2004, the cost of MM was estimated at €1634 per patient; this cost has not been re-estimated since. This study provided an update on survival and cost in real-life clinical practice.
Mots clés
Cost, Immunotherapy, Metastatic melanoma, Real-life clinical practice, Survival, Targeted therapy
Référence
Eur. J. Cancer. 2018 Oct 29;105:33-40